Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus

N/ACompletedNCT01916694

University of Oxford203 enrolled

Overview

Diabetes in pregnancy (gestational diabetes) is becoming more common. It can lead to problems for both mothers-to-be and their babies such as causing a large baby and difficult birth. Gestational diabetes in the mother may also lead to effects on the long term health of the baby. Most people today use mobile phones. Our research is looking at using a mobile phone app to help with diabetes care in pregnancy. In particular, the investigators are using phones which connect to the standard blood glucose monitoring machines given to all women with gestational diabetes to see if sending the hospital team blood test results between clinic appointments can result in the need for fewer clinic visits. The investigators are also testing to see how acceptable using mobile phones in this way, is to our patients and that the control of the blood glucose and outcomes for the mother and baby are at least as good as standard care. The investigators are planning to recruit 200 women who receive care for their gestational diabetes at the Oxford University Hospitals NHS (National Health Service) Trust. They will be randomised so that 100 will receive standard care, and 100 will have a mobile phone "app" linked to the blood glucose machines to send blood glucose readings directly to the diabetes care team to review. Both groups will be asked to test their blood glucose levels at home regularly with a glucometer. All participants will also be given lifestyle advice to reduce the chance they will need medication. Blood glucose control will be measured also by the percentage of glycated hemoglobin (HbA1c) at the time of diagnosis of gestational diabetes and before delivery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Enrollment

203

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pregnant women with an abnormal 75 gram 2 hour glucose tolerance test as defined by the IADPSG (International Association of Diabetes in Pregnancy Study Group) * Willingness and able to give informed consent * Female aged between 18-40 years * Singleton pregnancy * Able to travel to hospital independently Exclusion Criteria: * Impaired cognitive function such that she is unable to operate m-health equipment * Any evidence of fetal compromise * Known risk factors for obstetric complications, other than obesity and diabetes * Gestational diabetes requiring immediate pharmacologic treatment * Twins or higher order pregnancy * OGTT (Oral Glucose Tolerance Test) suggesting preexisting diabetes (fasting blood glucose \>= 7.0 or 2 hour \>= 11.1 mmol/L * Gestation greater than 34+6 at the time of potential recruitment * Unable to speak English well enough to explain or use equipment

Outcomes

Primary Outcomes

Glycosylated haemogloblin

Glycosylated haemoglobin (HbA1C) will be measured at the time of recruitment (around 28 weeks gestation) and at 36 weeks gestation. This will be approximately 8 weeks after recruitment (time 0).

Time frame: 8 weeks from recruitment at 28 weeks gestation to 36 weeks gestation

Secondary Outcomes

Mean Blood glucose levels for fasting, pre-prandial and post-prandial readings

Mean blood glucose levels for all readings measured fasting, pre-prandial and post prandial will be calculated over the 10 week participation in the trial (from recruitment at 28 weeks gestation to delivery at 38 weeks gestation).

Time frame: 10 weeks (from 28 weeks gestation to 38 weeks gestation)

Percentage of 'on target' blood glucose readings

Fasting readings as defined \>=3.5 and \<=5.8 mmol/L and post prandial readings \>= 3.5 and \<= 7.7 mmol/L for the first four weeks after randomisation and the second four weeks after randomisation

Time frame: 8 weeks (from recruitment at 28 weeks gestation to 36 weeks gestation)

Effectiveness of monitoring

Time to first trigger point (intensive dietary and lifestyle advice and increase monitoring to 7 days home per week) Time to second trigger point (insulin or metformin therapy) Time to treatment Number of changes to hypoglycaemics Maximum dose of insulin and metformin

Time frame: 10 weeks (from 28 weeks gestation to 38 weeks gestation)

Maternal outcomes

Perineal trauma (defined as third or fourth degree tear), pregnancy induced hypertension and preeclampsia, admission to higher level of care for mother. This will be measured up to 7 days post delivery (if birth is at 38 weeks, this will be 11 weeks after trial recruitment, unless birth occurs earlier)

Time frame: Approximately 11 weeks after recruitment

Maternal weight gain,

Weight gain in kilograms from trial recruitment until last antenatal visit prior to delivery

Time frame: 10 weeks (from 28 weeks gestation to 38 weeks gestation)

Birthweight

Z score of weight in kilograms for gestational age at delivery and Birthweight greater than 4.5kg

Time frame: At birth (approximately 10 weeks after trial recruitment)

Birth injury

Fracture of clavicle or humerus or other injury attributed to difficult birth, such as Erbs palsy or skull fracture

Time frame: At birth (approximately 10 weeks after trial recruitment)

Neonatal hypoglycaemia

Documented blood glucose level \<2.5mmol/L or requiring parenteral feeding within the first 48 hours of life after birth at around 38 weeks gestation (birth at approximately 10 weeks following trial recruitment and blood glucose monitoring in the neonate up to 48 hours after this)

Time frame: Approximately 10.5 weeks after recruitment

Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes